These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16523821)

  • 1. Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab.
    Fogarty GB; Bayne M; Bedford P; Bond R; Kannourakis G
    Clin Oncol (R Coll Radiol); 2006 Mar; 18(2):155-6. PubMed ID: 16523821
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab.
    Ollier L; Tieulie N; Sanderson F; Heudier P; Giordanengo V; Fuzibet JG; Nicand E
    Ann Intern Med; 2009 Mar; 150(6):430-1. PubMed ID: 19293084
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppressive drug therapy as a potentiator of skin tumours in five patients with lymphoma.
    Hill BH
    Australas J Dermatol; 1976 Aug; 17(2):46-8. PubMed ID: 1037366
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
    Orouji A; Goerdt S; Utikal J; Leverkus M
    Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
    [No Abstract]   [Full Text] [Related]  

  • 5. Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate.
    Fujii M; Iwasaki T; Takahashi I; Kishiyama K; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2015 Mar; 42(3):338-9. PubMed ID: 25580575
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy.
    Tsutsumi Y; Ichiki K; Shiratori S; Kawamura T; Tanaka J; Asaka M; Imamura M; Masauzi N
    Int J Lab Hematol; 2009 Aug; 31(4):468-70. PubMed ID: 18294236
    [No Abstract]   [Full Text] [Related]  

  • 7. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab.
    Chang H; Yeh HC; Su YC; Lee MH
    J Chin Med Assoc; 2008 Nov; 71(11):579-82. PubMed ID: 19015057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea.
    De Simone C; Guerriero C; Guidi B; Rotoli M; Venier A; Tartaglione R
    Eur J Dermatol; 1998 Mar; 8(2):114-5. PubMed ID: 9649662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkn's lymphoma patient.
    Unluturk U; Aksoy S; Yonem O; Bayraktar Y; Tekuzman G
    World J Gastroenterol; 2006 Mar; 12(12):1978-9. PubMed ID: 16610013
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Yang H; Rosove MH; Figlin RA
    Am J Hematol; 1999 Dec; 62(4):247-50. PubMed ID: 10589082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination treatment of a cutaneous non-Hodgkin's lymphoma with rituximab and polychemotherapy].
    Reinerth G; Bruch-Gerharz D; Kruse R; Bernhardt A; Schulte KW
    Hautarzt; 2007 Apr; 58(4):295-7. PubMed ID: 17333026
    [No Abstract]   [Full Text] [Related]  

  • 12. Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis.
    Ramamoorthy SK; Marangolo M; Durrant E; Akima S; Gottlieb DJ
    Leuk Lymphoma; 2006 Apr; 47(4):747-50. PubMed ID: 16690535
    [No Abstract]   [Full Text] [Related]  

  • 13. Malignancies after rituximab treatment: just coincidence or more?
    Aksoy S; Arslan C; Harputluoglu H; Dizdar O; Altundag K
    J BUON; 2011; 16(1):112-5. PubMed ID: 21674860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed-onset neutropenia associated with rituximab therapy.
    Chaiwatanatorn K; Lee N; Grigg A; Filshie R; Firkin F
    Br J Haematol; 2003 Jun; 121(6):913-8. PubMed ID: 12786803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Generalized lymphadenopathy and B symptoms].
    Nägelein R
    Internist (Berl); 2006 Sep; 47(9):974; author reply 974. PubMed ID: 17245841
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Squamous cell carcinoma in a patient receiving sorafenib].
    Adnot-Desanlis L; Bernard P; Reguiaï Z
    Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
    Ezra N; Hamid O; Behroozan D
    Dermatol Surg; 2012 Jul; 38(7 Pt 1):1086-90. PubMed ID: 22563699
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.
    Rashidi A; Oak E; Bartlett NL
    Blood; 2015 May; 125(21):3354-5. PubMed ID: 25999445
    [No Abstract]   [Full Text] [Related]  

  • 20. (18)F-FDG PET/CT imaging of squamous cell carcinoma induced by Vemurafenib.
    Nguyen BD
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):64-6. PubMed ID: 26251366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.